Transforming growth factor-beta blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after myocardial infarction.

After myocardial infarction (MI), the heart may undergo progressive ventricular remodeling, resulting in a deterioration of cardiac function. TGF-beta is a key cytokine that both initiates and terminates tissue repair, and its sustained production underlies the development of tissue fibrosis, particularly after MI. We investigated the effects of a novel orally active specific inhibitor of the TGF-beta receptor 1 (SD-208) in an experimental model of MI. Mice underwent ligation of the left coronary artery to induce MI and were subsequently treated for 30 d after infarction with either SD-208 or a vehicle control. Blockade of TGF-beta signaling reduced mean arterial pressure in all groups. SD-208 treatment after MI resulted in a trend for reduced ventricular and renal gene expression of TGF-beta-activated kinase-1 (a downstream modulator of TGF-beta signaling) and a significant decrease in collagen 1, in association with a marked decrease in cardiac mass. Post-MI SD-208 treatment significantly reduced circulating levels of plasma renin activity as well as down-regulating the components of the cardiac and renal renin-angiotensin system (angiotensinogen, angiotensin converting enzyme, and angiotensin II type I receptor). Our findings indicate that blockade of the TGF-beta signaling pathway results in significant amelioration of deleterious cardiac remodeling after infarction.

[1]  P. Sehgal,et al.  Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension. , 2008, American journal of respiratory and critical care medicine.

[2]  Gerard C Blobe,et al.  Role of transforming growth factor-beta superfamily signaling pathways in human disease. , 2008, Biochimica et biophysica acta.

[3]  Jinmai Jiang,et al.  TGF-beta1 stimulates human AT1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[4]  N. Frangogiannis,et al.  The role of TGF-β Signaling in Myocardial Infarction and Cardiac Remodeling , 2007 .

[5]  J. Mehta,et al.  The TGFβ superfamily in cardiovascular biology , 2007 .

[6]  V. Cameron,et al.  Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. , 2007, Journal of molecular endocrinology.

[7]  S. Ledbetter,et al.  Neutralization of transforming growth factor-β attenuates hypertension and prevents renal injury in uremic rats , 2005, Journal of hypertension.

[8]  G. Takemura,et al.  Postinfarction Gene Therapy Against Transforming Growth Factor-β Signal Modulates Infarct Tissue Dynamics and Attenuates Left Ventricular Remodeling and Heart Failure , 2005 .

[9]  M. Kolb,et al.  Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. , 2005, American journal of respiratory and critical care medicine.

[10]  S. Rosenkranz TGF-β1 and angiotensin networking in cardiac remodeling , 2004 .

[11]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[12]  G. Shen,et al.  Hirulog-like peptide reduces restenosis and expression of tissue factor and transforming growth factor-beta in carotid artery of atherosclerotic rabbits. , 2003, Atherosclerosis.

[13]  J. Massagué,et al.  Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.

[14]  S. Ledbetter,et al.  Antihypertensive effects of chronic anti-TGF-β antibody therapy in Dahl S rats , 2002 .

[15]  S. Rosenkranz,et al.  Alterations of β-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-β1 , 2002 .

[16]  M. Goumans,et al.  Transforming growth factor β signal transduction , 2002, Journal of leukocyte biology.

[17]  T. Doetschman,et al.  TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II , 2002 .

[18]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[19]  C. Lau,et al.  Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. , 2001, Journal of the American College of Cardiology.

[20]  A. Deten,et al.  Changes in extracellular matrix and in transforming growth factor beta isoforms after coronary artery ligation in rats. , 2001, Journal of molecular and cellular cardiology.

[21]  Shokei Kim,et al.  Effects of Combination of ACE Inhibitor and Angiotensin Receptor Blocker on Cardiac Remodeling, Cardiac Function, and Survival in Rat Heart Failure , 2001, Circulation.

[22]  V. Petrov,et al.  Induction of cardiac fibrosis by transforming growth factor-beta(1). , 2000, Molecular genetics and metabolism.

[23]  K. Weber,et al.  Connective tissue and the heart. Functional significance and regulatory mechanisms. , 2000, Cardiology clinics.

[24]  W A Hsueh,et al.  Angiotensin II, adhesion, and cardiac fibrosis. , 2000, Cardiovascular research.

[25]  Paul A. Overbeek,et al.  TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice , 2000, Nature Medicine.

[26]  Y. Sun,et al.  Cardiac remodeling by fibrous tissue after infarction in rats. , 2000, The Journal of laboratory and clinical medicine.

[27]  L. Field,et al.  Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart. , 2000, Circulation research.

[28]  Y. Yazaki,et al.  Role of the renin-angiotensin system in cardiac hypertrophy. , 1999, The American journal of cardiology.

[29]  I. Dixon,et al.  Elevation of expression of Smads 2, 3, and 4, decorin and TGF-beta in the chronic phase of myocardial infarct scar healing. , 1999, Journal of molecular and cellular cardiology.

[30]  L. Katwa,et al.  Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. , 1997, Journal of molecular and cellular cardiology.

[31]  Shokei Kim,et al.  Effects of an AT1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats , 1996, British journal of pharmacology.

[32]  N. Morisaki,et al.  In Vivo Effect of TGF-β1 , 1995 .

[33]  A. McCulloch,et al.  Angiotensin II stimulates the autocrine production of transforming growth factor-β1 in adult rat cardiac fibroblasts , 1995 .

[34]  Meihong Lin,et al.  Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. , 1995, The Journal of clinical investigation.

[35]  N. Takahashi,et al.  Hypertrophic stimuli induce transforming growth factor-beta 1 expression in rat ventricular myocytes. , 1994, The Journal of clinical investigation.

[36]  P. Dunn,et al.  Outpatient screening tests for primary aldosteronism. , 1976, Australian and New Zealand journal of medicine.

[37]  Shokei Kim,et al.  Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction. , 2003, Cardiovascular research.

[38]  J. Massagué,et al.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus. , 2003, Cell.

[39]  V. Lindner Vascular repair processes mediated by transforming growth factor-β , 2001, Zeitschrift für Kardiologie.

[40]  B. Swynghedauw,et al.  Molecular mechanisms of myocardial remodeling. , 1999, Physiological reviews.

[41]  Y. Sun,et al.  Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart. , 1998, Journal of molecular and cellular cardiology.

[42]  N. Morisaki,et al.  In vivo effect of TGF- beta 1. Enhanced intimal thickening by administration of TGF- beta 1 in rabbit arteries injured with a balloon catheter. , 1995, Arteriosclerosis, thrombosis, and vascular biology.